width=The A-T Children’s Project has begun exploring whether anti-inflammatory drugs might prevent or reduce lung problems that can become life-threatening for people with ataxia-telangiectasia. The organization has awarded funding to JoAnn Sekiguchi, PhD at the University of Michigan to determine if anti-inflammatory compounds can reduce lung damage in a mouse model of A-T.

About 25 percent of people with A-T develop lung disease. Problems with swallowing and aspiration, as well as weakened immune systems, lead to chronic lung disease. In addition, an inability to repair lung damage, premature aging, oxidative stress, and inflammation may contribute to the development of lung disease in A-T.

Dr. Sekiguchi and her laboratory will aim to learn if a certain type of immune cell, called a neutrophil, contributes to the over-active inflammatory response that occurs when the lungs of A-T mice are damaged. In hopes of finding a breakthrough approach to preventing lung damage in people with A-T, Dr. Sekiguchi’s team will test whether two compounds that target neutrophil-driven inflammation can reduce lung damage in A-T mice.

Oops! We could not locate your form.

Related News

Feb 29 @ 9:55 am

Looking Forward to Research Advances in 2024

Dear Friends, As 2023 is wrapping up, we want to thank all of you who support the A-T…

more
Feb 29 @ 9:55 am

A-T Biomarker Development Initiative Now Recruiting

On December 18, the A-T Children’s Project sent out the below email to A-T parents in the United…

more
Feb 29 @ 9:55 am

A-T Caregiver Weekend 2024 Announced

On December 15, the A-T Children’s Project sent the below email to parents inviting them to join us…

more
Feb 29 @ 9:55 am

Giving Tuesday Update 2023

It’s Giving Tuesday, and anonymous donors have joined together to match the first $60,000 in donations we receive!

more